- Analysis
- Barani Krishnan
- 19
MINAPHARM Pharmaceuticals produces medicines, medical and dental supplies, and dietary supplements in Egypt and internationally. The company produces veterinary and herbal medicines. It offers its products for the treatment of hematoma and thrombosis, iron deficiency anemia, recurrent urinary tract infections, immunostimulants, osteoporosis, renal osteodystrophy, loop diuretics, prophylaxis, hemorrhoids, rheumatoid arthritis, hyperlipidemia, alopecia, skin infections, topical corticosteroids, gynecological antifungals, vaginal infections, anti-infective, dyslipidemia, muscle spasm, dry eye, eye inflammation and allergy, corneal, nausea and vomiting, hepatology and gastroenterology, coronary heart, respiratory tract infections, occular irritation, labour induction, cerebral insufficiency, surgical dressing, prophylaxis, pregnancy and lactation, hemostasis, hemorrhage, infertility, glaucoma, ocular infection and inflammation, and microvascular diseases, as well as vitamin B12 deficiency, anemia, and diabetic neuropathy. MINAPHARM Pharmaceuticals was founded in 1958 and is based in Cairo, Egypt.
Metrics to compare | MIPH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMIPHPeersSector | |
---|---|---|---|---|
P/E Ratio | −9.4x | 12.3x | −0.6x | |
PEG Ratio | 0.06 | 0.08 | 0.00 | |
Price/Book | 0.4x | 2.0x | 2.6x | |
Price / LTM Sales | 0.4x | 1.1x | 3.1x | |
Upside (Analyst Target) | - | 19.6% | 48.8% | |
Fair Value Upside | Unlock | 15.4% | 7.5% | Unlock |